×
About 231,444 results

ALLMedicine™ Lung Cancer Center

Research & Reviews  107,037 results

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutat...
https://doi.org/10.1186/s12885-021-08266-w 10.1056/NEJMoa1809697 10.1016/j.annonc.2020.08.2281 10.1634/theoncologist.2019-0285 10.1016/j.chest.2019.03.033 10.3892/or.2018.6803 10.1667/RR14682.1 10.1186/s13045-016-0268-z
BMC Cancer; Zhu L, Zou C et. al.

May 8th, 2021 - Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth factor receptor-tyrosine kinase inhibit...

Climatic modification effects on the association between PM1 and lung cancer incidence ...
https://doi.org/10.1186/s12889-021-10912-8 10.1080/10473289.2006.10464485 10.1016/j.envint.2007.10.001 10.1016/j.envpol.2013.06.002 10.1136/bmj.315.7116.1161 10.1097/00001648-200109000-00011 10.1289/ehp.10851 10.1289/ehp.1002255 10.1016/j.envint.2019.105077 10.1289/ehp.10847 10.1177/1010539514529811 10.1016/j.envpol.2015.06.007 10.1016/j.envpol.2017.02.012 10.1289/ehp/1408092 10.1016/j.envres.2015.11.004 10.1016/j.envpol.2015.10.056 10.1016/j.envint.2018.09.033 10.1007/s00484-015-0984-z 10.1097/HJH.0000000000000738 10.1007/978-981-13-2583-0_7 10.1016/j.scitotenv.2012.07.008 10.1016/j.scitotenv.2016.10.033 10.1016/j.scitotenv.2019.134051 10.1016/j.atmosenv.2013.06.004 10.1016/j.envint.2014.07.009 10.1016/j.atmosenv.2014.09.071 10.2188/jea.JE20110049 10.1007/s11356-013-1688-8 10.1016/j.atmosenv.2012.07.011 10.1016/j.scitotenv.2019.03.049 10.1093/aje/kwn074 10.1016/j.atmosenv.2012.09.009 10.1016/j.scitotenv.2015.03.137 10.1042/CS20070444 10.1016/S2542-5196(17)30100-6 10.1016/j.envres.2004.01.015 10.1016/j.scitotenv.2011.02.005 10.1289/ehp.0800108 10.1289/EHP119 10.1016/S0140-6736(96)12338-2 10.1016/j.envres.2014.12.016 10.1289/ehp.1409671 10.1136/bmj.j667 10.1002/cncr.33078 10.1021/acs.est.9b03258 10.1016/j.atmosenv.2016.02.002 10.5194/acp-20-3273-2020 10.1016/j.rse.2020.112136 10.3390/rs12040663 10.1016/j.rse.2020.111697 10.1029/2019JD031155 10.1029/2019GL082781 10.3390/rs12071098 10.1016/j.scitotenv.2020.137664 10.1016/j.jes.2020.02.019 10.1257/aer.99.2.184 10.1073/pnas.1616784114 10.1016/j.envint.2018.04.021 10.1136/bmj.314.7095.1658 10.1136/oem.55.9.605 10.1016/j.atmosenv.2014.06.030 10.1016/j.atmosenv.2010.06.060 10.1289/ehp.0901181 10.1097/EDE.0000000000000269 10.1016/j.ijcard.2012.09.199 10.1016/j.atmosenv.2012.07.026 10.1016/j.atmosenv.2018.01.053 10.1080/19338240903240749
BMC Public Health; Guo H, Li X et. al.

May 8th, 2021 - Nationwide studies that examine climatic modification effects on the association between air pollution and health outcome are limited in developing countries. Moreover, few studies focus on PM1 pollution despite its greater health effect. This stu...

Influence of bilateral mediastinal lymph node dissection on survival in non-small cell ...
https://doi.org/10.1016/j.lungcan.2021.04.018
Lung Cancer (Amsterdam, Netherlands); Kużdżał J, Trybalski Ł et. al.

May 8th, 2021 - This study aimed to analyze the effect of bilateral mediastinal lymphadenectomy (BML) on survival of non-small cell lung cancer (NSCLC) patients. The hypothesis was: BML offers survival benefit as compared with SLND. A randomized clinical trial in...

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from ...
https://doi.org/10.1136/jitc-2020-001904
Journal for Immunotherapy of Cancer; Ramos-Paradas J, Hernández-Prieto S et. al.

May 8th, 2021 - Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content and algor...

see more →

Guidelines  653 results

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and ...
https://doi.org/10.1016/j.annonc.2021.03.207
Annals of Oncology : Official Journal of the European Soc... Dingemans AC, Früh M et. al.

Apr 17th, 2021 - Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dingemans AC,Früh M,Ardizzoni A,Besse B,Faivre-Finn C,|

Staged management of cardiac disease and concomitant early lung cancer: a 20-year single-center experience
https://pubmed.ncbi.nlm.nih.gov/33210113/
European Journal of Cardio-Thoracic Surgery; Tricard J

Apr 12th, 2021 - The association of unstable heart disease and resectable lung cancer is rare. The impacts of staged management, cardiac surgery with cardiopulmonary bypass (CPB) versus angioplasty, on long-term survival and cancer recurrence remain debated. We re...

Sensations, symptoms, and then what? Early bodily experiences prior to diagnosis of lung cancer
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249114
PLoS One; Bernhardson BM

Mar 28th, 2021 - Lung cancer (LC) generally lacks unique core symptoms or signs. However, there are a multitude of bodily sensations that are often non-specific, not easily understood, and many times initially not recognized as indicative of LC by the affected per...

The Aging Lung: Physiology, disease, and immunity
https://pubmed.ncbi.nlm.nih.gov/33811810/
Cell Schneider JL

Mar 25th, 2021 - The population is aging at a rate never seen before in human history. As the number of elderly adults grows, it is imperative we expand our understanding of the underpinnings of aging biology. Human lungs are composed of a unique panoply of cell t...

Prophylactic cranial irradiation for extensive‐stage small cell lung cancer
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014559/full
Cochrane Database of Systematic Reviews; Nishie K

Mar 17th, 2021 - To assess the effectiveness and safety of PCI plus standard treatment compared to standard treatment alone in people with ED‐SCLC who have responded to first‐line chemotherapy.

see more →

Drugs  381 results see all →

Clinicaltrials.gov  115,991 results

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutat...
https://doi.org/10.1186/s12885-021-08266-w 10.1056/NEJMoa1809697 10.1016/j.annonc.2020.08.2281 10.1634/theoncologist.2019-0285 10.1016/j.chest.2019.03.033 10.3892/or.2018.6803 10.1667/RR14682.1 10.1186/s13045-016-0268-z
BMC Cancer; Zhu L, Zou C et. al.

May 8th, 2021 - Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth factor receptor-tyrosine kinase inhibit...

Climatic modification effects on the association between PM1 and lung cancer incidence ...
https://doi.org/10.1186/s12889-021-10912-8 10.1080/10473289.2006.10464485 10.1016/j.envint.2007.10.001 10.1016/j.envpol.2013.06.002 10.1136/bmj.315.7116.1161 10.1097/00001648-200109000-00011 10.1289/ehp.10851 10.1289/ehp.1002255 10.1016/j.envint.2019.105077 10.1289/ehp.10847 10.1177/1010539514529811 10.1016/j.envpol.2015.06.007 10.1016/j.envpol.2017.02.012 10.1289/ehp/1408092 10.1016/j.envres.2015.11.004 10.1016/j.envpol.2015.10.056 10.1016/j.envint.2018.09.033 10.1007/s00484-015-0984-z 10.1097/HJH.0000000000000738 10.1007/978-981-13-2583-0_7 10.1016/j.scitotenv.2012.07.008 10.1016/j.scitotenv.2016.10.033 10.1016/j.scitotenv.2019.134051 10.1016/j.atmosenv.2013.06.004 10.1016/j.envint.2014.07.009 10.1016/j.atmosenv.2014.09.071 10.2188/jea.JE20110049 10.1007/s11356-013-1688-8 10.1016/j.atmosenv.2012.07.011 10.1016/j.scitotenv.2019.03.049 10.1093/aje/kwn074 10.1016/j.atmosenv.2012.09.009 10.1016/j.scitotenv.2015.03.137 10.1042/CS20070444 10.1016/S2542-5196(17)30100-6 10.1016/j.envres.2004.01.015 10.1016/j.scitotenv.2011.02.005 10.1289/ehp.0800108 10.1289/EHP119 10.1016/S0140-6736(96)12338-2 10.1016/j.envres.2014.12.016 10.1289/ehp.1409671 10.1136/bmj.j667 10.1002/cncr.33078 10.1021/acs.est.9b03258 10.1016/j.atmosenv.2016.02.002 10.5194/acp-20-3273-2020 10.1016/j.rse.2020.112136 10.3390/rs12040663 10.1016/j.rse.2020.111697 10.1029/2019JD031155 10.1029/2019GL082781 10.3390/rs12071098 10.1016/j.scitotenv.2020.137664 10.1016/j.jes.2020.02.019 10.1257/aer.99.2.184 10.1073/pnas.1616784114 10.1016/j.envint.2018.04.021 10.1136/bmj.314.7095.1658 10.1136/oem.55.9.605 10.1016/j.atmosenv.2014.06.030 10.1016/j.atmosenv.2010.06.060 10.1289/ehp.0901181 10.1097/EDE.0000000000000269 10.1016/j.ijcard.2012.09.199 10.1016/j.atmosenv.2012.07.026 10.1016/j.atmosenv.2018.01.053 10.1080/19338240903240749
BMC Public Health; Guo H, Li X et. al.

May 8th, 2021 - Nationwide studies that examine climatic modification effects on the association between air pollution and health outcome are limited in developing countries. Moreover, few studies focus on PM1 pollution despite its greater health effect. This stu...

Influence of bilateral mediastinal lymph node dissection on survival in non-small cell ...
https://doi.org/10.1016/j.lungcan.2021.04.018
Lung Cancer (Amsterdam, Netherlands); Kużdżał J, Trybalski Ł et. al.

May 8th, 2021 - This study aimed to analyze the effect of bilateral mediastinal lymphadenectomy (BML) on survival of non-small cell lung cancer (NSCLC) patients. The hypothesis was: BML offers survival benefit as compared with SLND. A randomized clinical trial in...

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from ...
https://doi.org/10.1136/jitc-2020-001904
Journal for Immunotherapy of Cancer; Ramos-Paradas J, Hernández-Prieto S et. al.

May 8th, 2021 - Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content and algor...

see more →

News  7,279 results

Fast Five Quiz: Squamous Cell Non-Small Cell Lung Cancer
https://reference.medscape.com/viewarticle/928233

May 4th, 2021 - Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Non–small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is divided histologically into adenocarcinoma, squamous cell carcinoma, and large cel...

Superior Survival With Sintilimab in Squamous NSCLC
https://www.medscape.com/viewarticle/950480

May 3rd, 2021 - Second-line treatment with sintilimab improved survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer (sqNSCLC) in a phase 3 trial. Sintilimab improved both overall survival (OS) and progre...

Small Cell Lung Cancer Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/950185

Apr 28th, 2021 - Updated guidelines on diagnosis, treatment, and follow-up of small cell lung cancer (SCLC) were published on April 9, 2021 by the European Society for Medical Oncology (ESMO) in the Annals of Oncology.[1] Diagnosis SCLC should be diagnosed accordi...

Tislelizumab Bests Docetaxel in NSCLC
https://www.medscape.com/viewarticle/949726

Apr 21st, 2021 - As second- or third-line therapy in patients with locally advanced non–small cell lung cancer (NSCLC), tislelizumab was well tolerated and prolonged overall survival (OS), compared with docetaxel in the phase 3 RATIONALE 303 study. The results wer...

Drug Duo Targeting ATR Enzyme Shrinks Small Cell Lung Cancer Tumors
https://www.medscape.com/viewarticle/949638

Apr 20th, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...

see more →

Patient Education  103 results see all →